Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Rationally designed multitarget anticancer agents.

Chen Z, Han L, Xu M, Xu Y, Qian X.

Curr Med Chem. 2013;20(13):1694-714. Review.

PMID:
23410168
2.

Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).

Marzaro G, Guiotto A, Chilin A.

Expert Opin Ther Pat. 2012 Mar;22(3):223-52. doi: 10.1517/13543776.2012.665876. Epub 2012 Mar 12. Review.

PMID:
22404097
3.

Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.

Seo SY.

Arch Pharm Res. 2012 Feb;35(2):197-200. doi: 10.1007/s12272-012-0221-9.

PMID:
22370774
4.

A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.

Chen Z, Liang X, Zhang H, Xie H, Liu J, Xu Y, Zhu W, Wang Y, Wang X, Tan S, Kuang D, Qian X.

J Med Chem. 2010 Mar 25;53(6):2589-600. doi: 10.1021/jm100025u.

PMID:
20170164
5.

Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.

Antonello A, Tarozzi A, Morroni F, Cavalli A, Rosini M, Hrelia P, Bolognesi ML, Melchiorre C.

J Med Chem. 2006 Nov 16;49(23):6642-5.

PMID:
17154492
6.

Naphthalimides and azonafides as promising anti-cancer agents.

Ingrassia L, Lefranc F, Kiss R, Mijatovic T.

Curr Med Chem. 2009;16(10):1192-213. Review.

PMID:
19355879
7.

Naphthalimide derivatives with therapeutic characteristics: a patent review.

Kamal A, Bolla NR, Srikanth PS, Srivastava AK.

Expert Opin Ther Pat. 2013 Mar;23(3):299-317. doi: 10.1517/13543776.2013.746313. Epub 2013 Feb 1. Review.

PMID:
23369185
8.

Novel naphthalimide derivatives as potential apoptosis-inducing agents: design, synthesis and biological evaluation.

Wu A, Xu Y, Qian X, Wang J, Liu J.

Eur J Med Chem. 2009 Nov;44(11):4674-80. doi: 10.1016/j.ejmech.2009.07.011. Epub 2009 Jul 16.

PMID:
19643513
9.

Overview of naphthalimide analogs as anticancer agents.

Lv M, Xu H.

Curr Med Chem. 2009;16(36):4797-813. Review.

PMID:
19929786
10.

Novel naphthalimide-amino acid conjugates with flexible leucine moiety as side chain: design, synthesis and potential antitumor activity.

Wu A, Xu Y, Qian X.

Bioorg Med Chem. 2009 Jan 15;17(2):592-9. doi: 10.1016/j.bmc.2008.11.080. Epub 2008 Dec 7.

PMID:
19109022
11.

Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1-c][1,4]benzodiazepine-naphthalimide conjugates linked through piperazine side-armed alkane spacers.

Kamal A, Ramu R, Tekumalla V, Khanna GB, Barkume MS, Juvekar AS, Zingde SM.

Bioorg Med Chem. 2008 Aug 1;16(15):7218-24. doi: 10.1016/j.bmc.2008.06.034. Epub 2008 Jun 25.

PMID:
18656370
12.

Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.

El-Azab AS, Eltahir KE.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1879-85. doi: 10.1016/j.bmcl.2012.01.071. Epub 2012 Jan 28.

PMID:
22326394
13.

Sulfur-substituted naphthalimides as photoactivatable anticancer agents: DNA interaction, fluorescence imaging, and phototoxic effects in cultured tumor cells.

Ott I, Xu Y, Liu J, Kokoschka M, Harlos M, Sheldrick WS, Qian X.

Bioorg Med Chem. 2008 Aug 1;16(15):7107-16. doi: 10.1016/j.bmc.2008.06.052. Epub 2008 Jul 2.

PMID:
18644732
14.

5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.

Xie L, Cui J, Qian X, Xu Y, Liu J, Xu R.

Bioorg Med Chem. 2011 Jan 15;19(2):961-7. doi: 10.1016/j.bmc.2010.11.055. Epub 2010 Nov 30.

PMID:
21208805
15.

Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.

Tan S, Yin H, Chen Z, Qian X, Xu Y.

Eur J Med Chem. 2013 Apr;62:130-8. doi: 10.1016/j.ejmech.2012.12.039. Epub 2013 Jan 3.

PMID:
23353750
16.

Selenium-containing naphthalimides as anticancer agents: design, synthesis and bioactivity.

Zhao L, Li J, Li Y, Liu J, Wirth T, Li Z.

Bioorg Med Chem. 2012 Apr 15;20(8):2558-63. doi: 10.1016/j.bmc.2012.02.049. Epub 2012 Mar 1.

PMID:
22436386
17.

Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents.

Alafeefy AM, Ashour AE.

J Enzyme Inhib Med Chem. 2012 Aug;27(4):541-5. doi: 10.3109/14756366.2011.601302. Epub 2011 Aug 18.

PMID:
21851213
18.

Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides.

Li F, Cui J, Guo L, Qian X, Ren W, Wang K, Liu F.

Bioorg Med Chem. 2007 Aug 1;15(15):5114-21. Epub 2007 May 17.

PMID:
17532640
19.

Unprecedented synthesis, in vitro and in vivo anti-cancer evaluation of novel triazolonaphthalimide derivatives.

Li S, Zhong W, Li Z, Meng X.

Eur J Med Chem. 2012 Jan;47(1):546-52. doi: 10.1016/j.ejmech.2011.11.025. Epub 2011 Nov 20.

PMID:
22138307
20.

A ROS-mediated lysosomal-mitochondrial pathway is induced by a novel Amonafide analogue, 7c, in human Hela cervix carcinoma cells.

Shen K, Sun L, Zhang H, Xu Y, Qian X, Lu Y, Li Q, Ni L, Liu J.

Cancer Lett. 2013 Jun 10;333(2):229-38. doi: 10.1016/j.canlet.2013.01.038. Epub 2013 Jan 29.

PMID:
23376642

Supplemental Content

Support Center